Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;479(5):1279-1295.
doi: 10.1007/s11010-023-04794-0. Epub 2023 Jul 7.

Noncoding RNAs in atherosclerosis: regulation and therapeutic potential

Luyao Qi  1 , Jixiang Xing  2 , Yuesong Yuan  3 , Ming Lei  4
Affiliations
Review

Noncoding RNAs in atherosclerosis: regulation and therapeutic potential

Luyao Qi et al. Mol Cell Biochem. 2024 May.

Abstract

Atherosclerosis, a chronic disease of arteries, results in high mortality worldwide as the leading cause of cardiovascular disease. The development of clinically relevant atherosclerosis involves the dysfunction of endothelial cells and vascular smooth muscle cells. A large amount of evidence indicates that noncoding RNAs, such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), are involved in various physiological and pathological processes. Recently, noncoding RNAs were identified as key regulators in the development of atherosclerosis, including the dysfunction of endothelial cells, and vascular smooth muscle cells and it is pertinent to understand the potential function of noncoding RNAs in atherosclerosis development. In this review, the latest available research relates to the regulatory role of noncoding RNAs in the progression of atherosclerosis and the therapeutic potential for atherosclerosis is summarized. This review aims to provide a comprehensive overview of the regulatory and interventional roles of ncRNAs in atherosclerosis and to inspire new insights for the prevention and treatment of this disease.

Keywords: Atherosclerosis; Endothelial; Noncoding RNAs; Smooth muscle cells; Therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Kobiyama K, Ley K. Atherosclerosis. Circ Res. 2018;123:1118–1120. doi: 10.1161/circresaha.118.313816. - DOI - PMC - PubMed
    1. Xu S, Pelisek J, Jin ZG. Atherosclerosis is an epigenetic disease. Trends Endocrinol Metab. 2018;29:739–742. doi: 10.1016/j.tem.2018.04.007. - DOI - PMC - PubMed
    1. Jia M, Li Q, Guo J, Shi W, Zhu L, Huang Y, Li Y, Wang L, Ma S, Zhuang T, Wang X, Pan Q, Wei X, Qin Y, Li X, Jin J, Zhi X, Tang J, Jing Q, Li S, Jiang L, Qu L, Osto E, Zhang J, Wang X, Yu B, Meng D. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022;130:1038–1055. doi: 10.1161/circresaha.121.319540. - DOI - PubMed
    1. Zhong L, Simard MJ, Huot J. Endothelial microRNAs regulating the NF-κB pathway and cell adhesion molecules during inflammation. FASEB J. 2018;32:4070–4084. doi: 10.1096/fj.201701536R. - DOI - PubMed
    1. Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, Saini AK. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev. 2020;2020:5245308. doi: 10.1155/2020/5245308. - DOI - PMC - PubMed

MeSH terms